石药集团(01093.HK)乙磺酸尼达尼布吸入粉雾剂在中国获临床试验批准
CSPC PHARMACSPC PHARMA(HK:01093) Jin Rong Jie·2026-01-04 02:41

Core Viewpoint - The approval of the inhaled powder formulation of Nintedanib by the National Medical Products Administration of China marks a significant milestone for the company, as it is the first inhalation formulation approved for clinical trials in China for the treatment of pulmonary fibrosis [1][1]. Group 1 - The inhaled formulation of Nintedanib has received approval for clinical trials in China [1]. - This product is the first of its kind in China specifically aimed at treating pulmonary fibrosis [1][1].